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Anita Thapar, MD, PhD, George Davey Smith, MD, DScObjective: Twin studies and genome-wide complex trait
analysis (GCTA) are not in agreement regarding herita-
bility estimates for behavioral traits in children from the
general population. This has sparked a debate on the
possible difference in genetic architecture between
behavioral traits and psychiatric disorders. In this study,
we test whether polygenic risk scores associated with
variation in attention-deﬁcit/hyperactivity disorder
(ADHD) trait levels in children from the general popula-
tion predict ADHD diagnostic status and severity in an
independent clinical sample.
Method: Single nucleotide polymorphisms (SNPs) with
p < .5 from a genome-wide association study of ADHD
traits in 4,546 children (mean age, 7 years 7 months) from
the Avon Longitudinal Study of Parents and Children
(ALSPAC; general population sample) were selected to
calculate polygenic risk scores in 508 children with an
ADHD diagnosis (independent clinical sample) and 5,081
control participants. Polygenic scores were tested forThis article is discussed in an editorial by Dr. Philip Asherson and
Dr. Maciej Trzaskowski on page 249.
Clinical guidance is available at the end of this article.
www.jaacap.orgassociation with case-control status and severity of disor-
der in the clinical sample.
Results: Increased polygenic score for ADHD traits pre-
dicted ADHD case-control status (odds ratio ¼ 1.17 [95%
CI ¼ 1.08–1.28], p ¼ .0003), higher ADHD symptom
severity (b ¼ 0.29 [95% CI ¼ 0.04–0.54], p ¼ 0.02), and
symptom domain severity in the clinical sample.
Conclusion: This study highlights the relevance of addi-
tive genetic variance in ADHD, and provides evidence
that shared genetic factors contribute to both behavioral
traits in the general population and psychiatric disorders
at least in the case of ADHD.
KeyWords: attention-deﬁcit/hyperactivitydisorder (ADHD),
polygenic risk scores, Avon Longitudinal Study of Parents
and Children (ALSPAC), common variants, genetics
J Am Acad Child Adolesc Psychiatry 2015;54(4):322–327.raditional behavioral genetic studies have shown that
psychiatric disorders, whether deﬁned categorically asT diagnoses or viewed as trait measures, are moderately
to highly heritable.1 Findings from these family, twin, and
adoption studies also suggest that many childhood psychi-
atric disorders, such as attention-deﬁcit/hyperactivity
disorder (ADHD),2,3 autism,4 and depression5 can be
viewed as extremes of dimensional attributes present in the
general population. Epidemiological studies similarly sug-
gest that many forms of psychopathology are underpinned
by dimensions because there appear to be no thresholds
beyond which links with risk factors and adverse outcomes
appear.3,6 This observation also applies to many physical
disorders such as obesity and cardiovascular disease.7,8
However, it has been much more difﬁcult to demonstrate
links between childhood behavioral traits and psychiatricdisorder at the level of molecular genetics.9 Moreover, there
is no evidence as yet to suggest whether the same risk alleles
that contribute to behavioral traits in the general population
also confer risk of psychiatric disorder.
Additive effects of common gene variants (single nucle-
otide polymorphisms [SNPs]), when jointly considered in
terms of estimated heritability or polygenic risk scores, have
been found to contribute to psychiatric disorders: specif-
ically ADHD, autism, depression, bipolar disorder, and
schizophrenia.10 A recent analysis of the largest international
dataset of these disorders found that variation tagged by
common SNPs explained 17% to 29% of variance in liabil-
ity.10 In contrast, common variants did not contribute to the
heritability of behavioral traits in children at age 12 from the
general population using genome-wide complex trait anal-
ysis (GCTA), although this was not the same for cognitive
traits.11 The difference in results between diagnoses and
dimensions could be methodological, perhaps due to the fact
that case-control studies analyze hypothetical constructs of
continuous liabilities. However, it has been suggested that
perhaps the genetic architecture of psychiatric disorders is
different to that of behavioral traits.12 Given that this is not
what is suggested by epidemiological studies of behavioralJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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SHARED GENETIC INFLUENCES BETWEEN ADHD TRAITStraits in children during early childhood or late adolescence,4
this hypothesis needs to be tested directly.
Previous research suggests that polygenic risk scores can
distinguish children with clinically diagnosed ADHD from
control participants.13 There is also some evidence that for
ADHD, at least, polygenic risk scores associated with cate-
gorical diagnosis contribute to trait variation in individuals
from the general population without the disorder. We pre-
viously found that polygenic risk scores associated with
ADHD diagnosis predicted ADHD trait levels in children
from the general population.14
In thepresent study,wederivedpolygenic riskscores froma
discovery genome-wide association study (GWAS) of ADHD
traits in a general population sample to test whether common
genetic risk alleles associated with variation in ADHD trait
levels predict ADHD diagnostic status and also the severity of
disorder inan independent clinical case-controlADHDsample.
METHOD
The polygenic risk score method described by the International
Schizophrenia Consortium (ISC) was used in this analysis.15 A dis-
covery quantitative GWAS of ADHD traits in the Avon Longitudi-
nal Study of Parents and Children (ALSPAC) was used to identify
risk alleles associated with higher levels of ADHD traits. Polygenic
risk scores based on these population risk alleles were then calcu-
lated in the target patient sample, which was a published GWAS of
British children with ADHD and population controls.16
Avon Longitudinal Study of Parents and Children
(ALSPAC)—Discovery Sample
ALSPAC, which was used as the discovery sample for this study, is a
prospective birth cohort that recruited pregnant womenwith expected
delivery dates between April 1991 and December 1992 from Bristol,
United Kingdom. A total of 14,541 pregnant women were initially
enrolled,with 14,062 childrenborn.Detailed informationonhealth and
development of children and their parents was collected from regular
clinic visits and completion of questionnaires. A detailed description of
the cohort has been published previously.17,18 The study website con-
tains details of all data that are available through a fully searchabledata
dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/
data-dictionary/). Ethical approval was obtained from the ALSPAC
Law and Ethics Committee and the local ethics committees.
ALSPAC GWAS Data
A total of 9,912 research participants were genotyped using the Illu-
mina HumanHap550 quad genome-wide SNP genotyping platform
by the Wellcome Trust Sanger Institute (Cambridge, UK) and the
Laboratory Corporation of America (Burlington, NC) using support
from 23andMe. Details on the quality control (QC) procedure haveTABLE 1 Descriptive Statistics for Avon Longitudinal Study of Pare
(GWAS) and Cases From Attention-Deficit/Hyperactivity Disorder (
n
% Male
Age in months, mean (SD)
ADHD traits/clinical symptoms, n (SD) [range]
Full Scale IQ, mean (SD)
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participants and 500,527 SNPs available for analysis. Association
analyses were performed under an additive model using PLINK,20
with sex included in the analysis as a covariate.
Phenotypic Measures
ADHD traits were assessed in ALSPAC when the participants were
7 years 7 months of age using the parent-completed Development
and Well-Being Assessment (DAWBA).21 The time point was chosen
to be as close as possible to the mean age of children with ADHD in
the target sample while at the same time maximizing sample size.
For each ADHD item, parents marked boxes to say whether their
child showed the behavior; these were coded 0 for “no,” 1 for “a
little more than others,” and 2 for “a lot more than others.” A total
ADHD trait score was calculated by summing these responses to
give a possible range of 0 to 36. Scores on measures with less than
30% missing items were mean imputed. IQ was assessed using a
short form of the Wechsler Intelligence Scale for Children (WISC)–III
assessment with alternate items from all 10 subtests administered.22
The GWAS was performed after excluding children with a diagnosis
of autism spectrum disorder (ASD), those with Full Scale IQ less
than 70, and those for whom there were no data available on ASD
diagnosis or IQ, to follow the exclusion criteria that were used in the
target sample.16 In all, 4,546 children had both phenotypic and ge-
netic data available for analysis, with 2,259 (49.7%) of them being
male. A total of 78 children (1.7%) had an ADHD diagnosis (any
type) with the majority (70) of them being male.
Target ADHD Clinical Sample
The target sample consistedofBritish childrenwith a conﬁrmedDSM-
IV research diagnosis of ADHD (N¼ 508) recruited from community
child and adolescent mental health and child health clinics. Trained
interviewersused theChild andAdolescentPsychiatricAssessment—
Parent Version,23 a semi-structured research diagnostic interview, to
assess psychiatric diagnoses. DSM-IV ADHD and symptom domain
severity were calculated by summing scores on ADHD items.
Pervasiveness of ADHD symptoms (in school) was assessed using the
Child Attention-Deﬁcit Hyperactivity Disorder Teacher Telephone
Interview24 or the Conners Teacher Questionnaire.25 Individuals in
the ADHD sample had a conﬁrmed lifetime diagnosis of ADHD, but
some had remitted symptoms at the time of assessment and are
excluded from the analysis of symptom severity.
IQ was assessed using the WISC-IV.26 The children in this study
were between 5 and 17 years of age (mean ¼ 10.5, SD ¼ 2.8 years),
and 443 (87.2%) were male.
DNA samples from children with ADHD were genotyped on
the Illumina Human660W-Quad BeadChip, and control participants
were genotyped by the Wellcome Trust Case Control Consortium–
Phase2 using the Illumina Human 1.2M BeadChip.27 Control partici-
pants comprised 3,000 individuals born in the UnitedKingdomduring
1 week in 1958 (the 1958 British Birth Cohort) and 3,000 individuals
from the UK Blood Services collection. It has previously been shownnts and Children (ALSPAC) Genome-Wide Association Study
ADHD) Clinical Sample
ALSPAC GWAS ADHD Clinical Sample Cases
4,546 508
49.7 87.2
91.8 (1.7) 126 (33.6)
4.6 (6.4) [0-36] 14.7 (2.8) [0-18]
106.6 (15.6) 87.2 (11.2)
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TABLE 2 Linear Regression of Polygenic Scores for Attention-
Deficit/Hyperactivity Disorder (ADHD) Traits on the Total
Number of ADHDSymptoms and SymptomDomains in Children
With an ADHD DSM-IV Diagnosis
Outcome b Coefﬁcient (95% CI)
p
Value R2 n
Total no. of DSM-IV
ADHD symptoms
0.29 (0.04 to 0.54) .02 0.011 484
Total no. of DSM-IV
inattentive symptoms
0.17 (0.02 to 0.33) .03 0.01 493
Total no. of DSM-IV
hyperactive/impulsive
symptoms
0.14 (0.01 to 0.29) .06 0.007 497
Note: n differs from case-control analysis because of individuals with remitted
symptoms at the time of assessment who are excluded from the analysis of
symptom severity.
STERGIAKOULI et al.that it is valid to combine these 2 samples for use as control partici-
pants in genetic association studies using UK case samples.28 The
GWAS case-control analysis was based on 502,702 genotyped SNPs
present on both chips after QC. Details on the QC procedure and
results on this GWAS have been described previously.16
The target sample was selected for this study due to its similarity
to the ALSPAC study both in terms of ethnicity and geographic
location, as well as its robust diagnostic assessment process.
Research participants in the target and discovery samples were
recruited from geographically nearby regions (Southwest England
and Wales). Therefore, an identity by descent (IBD) analysis was
conducted using PLINK20 to ensure that there would be no related
individuals between the 2 samples. Two individuals in the clinical
ADHD sample who showed IBD of 12.5% or more in relation to
individuals in the discovery sample were removed from all analyses.
Statistical Analysis
To identify risk alleles in the ALSPAC discovery sample (quantita-
tive GWAS of ADHD traits), we selected SNPs with a threshold of
p < 0.5, in line with previous studies.15,29
SNPs in linkage equilibrium in the Cardiff clinical sample were
identiﬁed using PLINK15 (–indep-pairwise 200 5 0.2) with a sliding
window of 200 SNPs, moving it along the genome 5 SNPs at a time
and dropping an SNP when the pairwise estimate of linkage
disequilibrium (LD;r2) exceeded 0.2.
The SNPs that were present in both the list of risk alleles from
ALSPACand the LD-pruned list fromCardiff (n¼ 231,488)were used
to calculate a polygenic score for each individual in theCardiff clinical
sample, which was a sum of all risk alleles weighted by b coefﬁcient
using the PLINK command (–score) with imputation of missing
genotypes. The resulting polygenic scores were standardized using
z-score transformation and tested for association with ADHD case-
control status in the Cardiff sample using logistic regression with
sex as a covariate. They were also tested for association with total
number of DSM-IV ADHD inattentive and hyperactive/impulsive
symptoms, using linear regression with sex as a covariate. The
amount of variance explained was calculated as the difference of
Nagelkerke’s pseudo-R2 in the full model as compared to the null
model, which included sex but not polygenic score. p Values were
determined from likelihood ratio tests, which compare the full model
to the null model. In addition, conditional analysis was performed
with hyperactive/impulsive symptoms included as a covariate in the
model for inattentive symptoms and inattentive symptoms included
as a covariate in the model for hyperactive/impulsive symptoms to
test whether any particular ADHD symptom domain was contrib-
uting more to the association. Statistical analyses were performed
using Stata Statistical Software Release 13.30
RESULTS
In this study, we used risk alleles from a GWAS of ADHD
traits in the general population to calculate polygenic risk
scores in a clinical sample of children with ADHD and
population cohorts. Table 1 describes the characteristics of
individuals used in the discovery sample (ALSPAC GWAS)
and the target sample (ADHD clinical sample).
Polygenic risk scores were calculated in the Cardiff cases
and controls based on the results of the GWAS of ALSPAC
ADHD traits. To test whether increased polygenic score for
ADHD traits was associated with case-control status in the
clinical study, logistic regression of polygenic risk scores for
ADHD traits on 508 individuals with ADHD and 5,081
control participants was used. Results show that population324 www.jaacap.orgADHD trait polygenic scores signiﬁcantly distinguish par-
ticipants with ADHD from controls (odds ratio [OR] ¼ 1.17
[95% CI ¼ 1.08–1.28], p ¼ .0003, pseudo-R2 ¼ 0.004).
Table 2 shows the results of association between trait
polygenic scores derived from the ALSPAC GWAS and
DSM-IV ADHD symptom severity and ADHD symptom
domain scores in the clinical sample. Increased genetic load
for ADHD traits predicted higher ADHD symptom severity
in the clinical sample (b ¼ 0.29 [95% CI ¼ 0.04–0.54], p ¼ .02,
pseudo- R2 ¼ 0.011), as well as symptom domain severity.
The association with inattentive symptoms (b ¼ 0.17
[95% CI ¼ 0.02–0.33], p ¼ .03, pseudo-R2 ¼ 0.01) was
stronger than that for hyperactive/impulsive symptoms
(b ¼ 0.14 [95% CI ¼ 0.01 to 0.29], p ¼ .06, pseudo-R2 ¼
0.007), but the direction of effect was as expected.
Table 3 describes the results of the conditional analysis
with hyperactive/impulsive symptoms included as a covari-
ate in the model for inattentive symptoms and inattentive
symptoms included as a covariate in the model for hyperac-
tive/impulsive symptoms. The magnitude of association of
ADHD trait scores with inattentive symptoms was reduced
when adjusting for hyperactive/impulsive symptoms, but the
direction of effectwas still as expected.However, therewas no
association of ADHD trait scoreswith hyperactive/impulsive
symptoms when adjusting for inattentive symptoms, which
suggests that inattentive symptoms contributed more to the
association than hyperactive/impulsive symptoms.DISCUSSION
The present study is the ﬁrst to show, using molecular
genetics, that the same risk alleles contributing to ADHD
trait levels in the general population also confer risk of
ADHD diagnosis and increased symptom severity. ADHD
trait polygenic risk scores distinguished case individuals
with an ADHD diagnosis from general population controls
and were associated with a higher number of ADHD
symptoms in individuals with an ADHD diagnosis.
Polygenic risk score analysis is well suited for phenotypes
such as ADHD. ADHD is a heritable disorder with twinJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 3 Conditional Linear Regression of Polygenic Scores
for Attention-Deficit/Hyperactivity Disorder (ADHD) Traits on
ADHD Symptom Domains in Children With an ADHD DSM-IV
Diagnosis
Outcome b Coefﬁcient (95% CI)
p
Value R2 n
Total no. of DSM-IV
inattentive symptoms
adjusting for
hyperactive symptoms
0.13 (0.02 to 0.27) .09 0.002 493
Total no. of DSM-IV
hyperactive/impulsive
symptoms adjusting
for inattentive
symptoms
0.08 (0.06 to 0.22) .26 0.005 493
SHARED GENETIC INFLUENCES BETWEEN ADHD TRAITSheritability estimates at 76%31 and SNP heritability of 24% to
32% according to the latest cross-disorder analysis.10 Common
genetic variants have been shown to be involved in ADHD at
the disorder level.16 However, no speciﬁc genetic variants have
been robustly associated yet in a hypothesis-free GWAS of
ADHD.16,32 This is likely attributable to the smaller sample sizes
compared to those for other psychiatric disorders with similar
heritability. For example, 128 independent SNPs spanning 108
distinct loci for schizophrenia were recently identiﬁed when
sample sizes increased to >80,000 individuals.33 For these rea-
sons, research on common genetic variants in ADHD has star-
ted focusing on methods that consider common variants from
GWAS as an aggregate, namely polygenic risk score analysis.
There is evidence that polygenic scores for clinical ADHD can
predict case-control status in an independent sample.13 In
addition, we have previously shown that polygenic risk scores
derived from clinical patients with ADHD predict ADHD trait
level in the general population.14 We now provide evidence
using molecular genetics that common gene variation that
contributes to ADHD trait levels in the general population is
also relevant to risk of clinical disorder and its severity. This is
especially pertinent because the amount of variance explained
by common variants for behavioral traits in the general popu-
lationhasbeen considered too lowtobe relevant to thedisorder,
and ithasbeensuggested that theheritabilityofbehavioral traits
has a large nonadditive genetic inﬂuence.11
These ﬁndings have important implications for ADHD
research. First, they provide further support to the notion that
ADHD as a disorder lies on the spectrum of normal trait
variation. Family and twin studies have already shown that a
clinical diagnosis of ADHD in one sibling is associated with
increasedADHD trait scores in the unaffected sibling.34,35 The
present study suggests that, at least at the level of common
genetic variants, genetic risk factors for subthreshold ADHD
traits present in individuals from the general population and
thosewith the clinical disorder overlap, although the extent of
overlap could be limited given small effect sizes. Similar re-
sults have been found for physical conditions that are
underpinned by continuously distributed risk dimensions
(for example, polygenic risk scores for type 2 diabetes are
associated with fasting glucose in the general population36),JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 54 NUMBER 4 APRIL 2015strengthening the notion that complex disorders are, in fact,
quantitative traits,37 and presenting clinicians with the chal-
lenge to determine diagnostic and treatment thresholds. Our
ﬁndings raise questions about the arbitrariness of thresholds
used for diagnosis and treatment in psychiatric disorders,
especially when children with subthreshold ADHD cannot
beneﬁt from access to special educational services. This,
together with ﬁndings that high levels of ADHD traits in
children from the general population carry risk of worse ac-
ademic performance,38 suggests that more research is
required to investigate whether recognizing ADHD symp-
toms, even subthreshold, at an early stage and offering
appropriate support can reduce the risk of educational un-
derachievement and problematic behaviors.
More importantly, these results are relevant to the debate of
whether the genetic architecture of behavioral traits differs
from that of other quantitative traits. A recent molecular ge-
netic study of twins reported a discrepancy of heritability
estimates for behavioral traits between twin estimates and
GCTA in the same sample of children at age 12 years.11 No
genetic inﬂuence for behavioral traits could be detected using
GCTA at age 12 years, whereas heritability estimates from the
twin design were substantial, and others report signiﬁcant
GCTA estimates for social communication traits in older age
groups.4 Both GCTA and the twin design showed substantial
heritability for cognitive and anthropometric traits in the same
sample.11 This has led to speculation that additive genetic in-
ﬂuences might not be as relevant for behavioral traits as they
are for other quantitative traits or that the phenotype assess-
ment based on questionnaire ratings rather than standardized
tests inﬂuences heritability estimates. GCTA was not appro-
priate for ADHD traits in ALSPAC, given that the variable is
highly skewed and difﬁcult to transform appropriately. Using
polygenic risk score analysis, we were able to counter these
suggestions by showing that additive genetic variance was
relevant for ADHD even when it was based on ADHD trait
scores measured in children from the general population. The
discrepancy of our results with recent GCTA reports could be
due to a number of factors. First of all, we had a larger sample
size of 4,546 children available as compared to 2,500 unrelated
individuals in the previous report.11 ADHD traits in children
were assessed with the DAWBA, which is a semi-structured
diagnostic interview. The use of more clinically rigorous in-
struments for assessing symptoms can inﬂuence results in this
type of analysis. Finally, the ALSPAC sample is very homo-
geneous in terms of ancestry, as all participants are from the
Bristol area in the United Kingdom.
Adjustment of the associations with ADHD symptom
domains suggests that the association of ADHD trait scores
with the number of ADHD symptoms is driven by inatten-
tive symptoms rather than hyperactive/impulsive symp-
toms. This could indicate that the genetic component of
inattentive symptoms is stronger than that for hyperactive/
impulsive symptoms. An alternative explanation could be
that genetic inﬂuences on hyperactive/impulsive symptoms
that do not overlap with genetic inﬂuences on inattentive
symptoms may contribute more to ADHD traits in the
general population. Although some twin studies have found
distinct genetic inﬂuences on symptom domains, thewww.jaacap.org 325
STERGIAKOULI et al.evidence on the whole is not compelling.39 Indeed, ADHD
subtype diagnoses have been removed in the DSM-5, and
they serve only as descriptive speciﬁers. Despite the lack of
distinct genetic inﬂuences for ADHD symptom domains,
inattentive symptoms are developmentally more persistent
than hyperactive/impulsive symptoms.40
Our study beneﬁts from a large discovery population
sample that is not only ancestrally similar to the well-
characterized clinical sample used but also geographically
adjacent (while any related individuals between the samples
were removed from the analysis). Both samples are homo-
geneous in terms of their ancestry and also diagnostic
assessment. Although each study used different diagnostic
instruments, the assessment within each sample was stan-
dardized across all individuals.
A limitation of the study is that there is no phenotypic
information available on the controls in the case-control
ADHD study. This means that there could be individuals
with ADHD in the control sample that we were unable to
identify. However, this would only reduce our power to
distinguish between individuals with ADHD and controls.
In a future study, it would be interesting to test whether
polygenic scores were associated with ADHD trait levels in
individuals from another general population cohort. Un-
fortunately this was not possible in this study because of
the lack of ADHD trait scores in the control sample.
As a longitudinal study, the ALSPAC cohort suffers from
attrition that could be associated with behavioral problems,
such as ADHD. In this case, the predictive power of the
polygenic scores would be reduced and the associations
with ADHD would be weaker. However, the prevalence of
ADHD in the ALSPAC sample was 3.1% for boys and 0.3%
for girls, which is very similar to the UK prevalence for
ADHD during childhood (2.7% for boys and 0.4% for
girls).41 Multiple imputation methods for missing data have
been applied to ALSPAC ADHD data previously but did not
have an effect on the association patterns.42
Another potential issue that should be discussed is that
because the target sample consists of children who alreadyClinical Guidance
 Genetic risk factors for subthreshold ADHD traits present in
individuals from the general population and those with the
clinical disorder overlap.
 There is further support to the notion that ADHD as a
disorder lies on the spectrum of normal trait variation.
 Additive genetic variance is relevant to the genetic
architecture of behavioral traits not unlike other quantitative
traits.
 More research is required to investigate whether
recognizingADHDsymptoms, even subthreshold symptoms,
at an early stage and offering appropriate support could
reduce the risk of educational underachievement and
problematic behaviors.
326 www.jaacap.orghave a diagnosis of ADHD, a signiﬁcant proportion of them
were likely to be on medication that reduces ADHD symp-
tom severity. Although this would have an impact on the
power to detect an association with the number of ADHD
symptoms, it would not have an impact on our ability to
distinguish between individuals with ADHD and controls,
because children with ADHD had a lifetime diagnosis based
on symptoms present before initiation of medication.
In summary, polygenic scores for ADHD trait levels in
the general population are associated with an ADHD diag-
nosis and with symptom severity for those with the disor-
der. This study highlights the importance of common genetic
variants for ADHD traits and the dimensionality of the
ADHD phenotype. It also counters suggestions that the ge-
netic architecture of behavioral traits is different from that of
other complex traits. &
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